Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model

Signal Transduct Target Ther. 2022 Apr 16;7(1):123. doi: 10.1038/s41392-022-00963-7.

Ruxue Zhang^#^{1

2}, Yumin Zhang^#¹, Wei Zheng^#^{2

3}, Weijuan Shang¹, Yan Wu¹, Ning Li⁴, Jun Xiong⁴, Hualiang Jiang^{2

3}, Jingshan Shen^{2

3}, Gengfu Xiao^{1

2}, Yuanchao Xie^{5

6}, Leike Zhang^{7

8}

¹ State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
² University of Chinese Academy of Sciences, Beijing, 100049, China.
³ Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
⁴ Shanghai Junshi Biosciences Co., Ltd., Shanghai, 200126, China.
⁵ Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xieyuanchao@simm.ac.cn.
⁶ Lingang Laboratory, Shanghai, 200031, China. xieyuanchao@simm.ac.cn.
⁷ State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China. zhangleike@wh.iov.cn.
⁸ University of Chinese Academy of Sciences, Beijing, 100049, China. zhangleike@wh.iov.cn.

^# Contributed equally.

No abstract available

Publication types